Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center

Protein-losing enteropathy (PLE) is a complication in some systemic lupus erythematosus (SLE) patients that is often misdiagnosed. With this study, we provide insight into clinical characteristics, laboratory characteristics, diagnostic tests, risk factors, treatment, and prognosis of the disease. A...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-12, Vol.9 (12), p.e114684-e114684
Main Authors: Chen, Zhen, Li, Meng-Tao, Xu, Dong, Yang, Hong, Li, Jing, Zhao, Jiu-Liang, Zhang, Heng-Hui, Han, Shao-Mei, Xu, Tao, Zeng, Xiao-Feng
Format: Article
Language:English
Subjects:
Active control
Adolescent
Adult
Aged
Albumin
Arthritis
Autoimmune diseases
Case-Control Studies
Cholesterol
Cholesterol - blood
Chronic conditions
Classification
Complement C3 - metabolism
Control methods
Corticoids
Corticosteroid drugs
Corticosteroids
Cyclophosphamide - therapeutic use
Diagnostic systems
Disease control
Edema
Education
Epidemiology
Female
Glucocorticoids - therapeutic use
Hospitals
Humans
Hypercholesterolemia
Immunology
Immunosuppressive agents
Immunosuppressive Agents - therapeutic use
Laboratories
Likelihood ratio
Liver diseases
Lupus
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - drug therapy
Male
Medical treatment
Medicine and Health Sciences
Middle Aged
Nephrology
Patients
Prognosis
Protein-Losing Enteropathies - complications
Protein-Losing Enteropathies - diagnosis
Protein-Losing Enteropathies - drug therapy
Proteins
Proteinuria
Retrospective Studies
Rheumatology
Risk analysis
Risk Factors
Science
Serum Albumin
Systematic review
Systemic lupus erythematosus
Treatment Outcome
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein-losing enteropathy (PLE) is a complication in some systemic lupus erythematosus (SLE) patients that is often misdiagnosed. With this study, we provide insight into clinical characteristics, laboratory characteristics, diagnostic tests, risk factors, treatment, and prognosis of the disease. A retrospective, case-control study was performed in 44 patients with SLE-related PLE (PLE group) and 88 patients with active SLE (control group) admitted to our care from January 2000-January 2012. Risk factors for SLE-related PLE were examined, and we analyzed the accuracy of single and combined laboratory characteristics in discriminating SLE-related PLE from active SLE. Serum albumin and C3 levels were measured as outcome during and after treatment with corticosteroids and immunosuppressive agents. The PLE group had lower mean serum albumin and 24-hour urine protein levels, higher mean total plasma cholesterol levels, and greater frequencies of anti-SSA and SSB seropositivity compared with the control group. Anti-SSA seropositivity, hypoalbuminemia, and hypercholesterolemia were independent risk factors for SLE-related PLE. The simultaneous presence of serum albumin (
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0114684